Maria Edilene Martins de Almeida

Maria Edilene Martins de Almeida

Auto-generated profile, based on publicly available information

Maria Edilene Martins de Almeida

Fundação Oswaldo Cruz, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Revista do Instituto de Medicina Tropical de São Paulo
Verified
Journal Article
Open access
PDF file
MAMaria Edilene Martins de Almeida
Maria Edilene Martins de Almeida
MVMaria Gabriella Santos de Vasconcelos
Maria Gabriella Santos de Vasconcelos
ATAndrea Tarragô
Andrea Tarragô
LMLuís André Morais Mariúba
Luís André Morais Mariúba
Malaria represents a serious public health problem, presenting with high rates of incidence, morbidity and mortality in tropical and subtropical regions of the world. According to the World Health Organization, in 2018 there were 228 million cases and 405 thousand deaths caused by this disease in the world, affecting mainly children and pregnant women in Africa. Despite the programs carried out to control this disease, drug resistance and invertebrate vector resistance to insecticides have generated difficulties. An efficient vaccine against malaria would be a strategy with a high impact on the eradication and control of this disease. Researches aimed at developing vaccines have focused on antigens of high importance for the survival of the parasite such as the Circumsporozoite Surface Protein, involved in the pre-erythrocytic cycle during parasites invasion in hepatocytes. Currently, RTS’S is the most promising vaccine for malaria and was constructed using CSP; its performance was evaluated using two types of adjuvants: AS01 and AS02. The purpose of this review was to provide a bibliographic survey of historical researches that led to the development of RTS’S and its performance analysis over the decade. The search for new adjuvants to be associated with this antigen seems to be a way to obtain higher percentages of protection for a future malaria vaccine.

1 January 2022 in Revista do Instituto de Medicina Tropical de São Paulo
Verified
Journal Article
Open access
KAKéssia Caroline Souza Alves
Késsia Caroline Souza Alves
JGJander Matos Guimarães
Jander Matos Guimarães
MAMaria Edilene Martins de Almeida
Maria Edilene Martins de Almeida
LMLuis André Mariuba
Luis André Mariuba
Despite the many efforts of researchers around the world, there is currently no effective vaccine for malaria. Numerous studies have been developed to find vaccine antigens that are immunogenic and safe. Among antigen candidates, Plasmodium falciparum merozoite surface protein 3 (MSP3) has stood out in a number of these studies for its ability to induce a consistent and protective immune response, also being safe for use in humans. This review presents the main studies that explored MSP3 as a vaccine candidate over the last few decades. MSP3 formulations were tested in animals and humans and the most advanced candidate formulations are MSP3-LSP, a combination of MSP3 and LSP1, and GMZ2 (a vaccine based on the recombinant protein fusion GLURP and MSP3) which is currently being tested in phase II clinical studies. This brief review highlights the history and the main formulations of MSP3-based vaccines approaches against P. falciparum .

1 January 2025 in Cadernos de Saude Publica
Verified
Journal Article
Open access
RVRosiane Mendes Valente
Rosiane Mendes Valente
JVJoão Victor de Melo Verçosa
João Victor de Melo Verçosa
ESEduardo Rodrigues de Souza
Eduardo Rodrigues de Souza
NGNatalia Prata Gordiano
Natalia Prata Gordiano
LBLayssa Do Carmo Barroso
Layssa Do Carmo Barroso
AJAni Jackisch-Matsuura
Ani Jackisch-Matsuura
Sporotrichosis is an emerging fungal infection that has been causing concern in Brazil since the late 1990s and is the most prevalent and globally distributed among implantation mycoses. In Brazil, the increase in sporotrichosis cases is strongly associated with infections in cats. This study aimed to identify the epidemiological profile and expansion of sporotrichosis in the city of Manaus, Amazonas State, Brazil, based on cases reported from 2020 to 2023. Secondary data from confirmed sporotrichosis cases during this period in Manaus were employed. Human data were extracted from the Brazilian Information System for Notificable Diseases, the Manaus Municipal Health Department, and the RedCap database of the Amazonas Health Surveillance Foundation - Registry of Positive Cases. The animal data were extracted from the spreadsheet of the Dr. Carlos Durand Zoonoses Control Center in Manaus. Data analysis was performed using the RStudio software for the spatial distribution of cases in the QGIS program, which was used to define the areas with the highest absolute number of cases. From August 2020 to December 2023, 4,301 sporotrichosis cases were confirmed, including 3,403 animal cases (of which 99.6% involved cats) and 898 human cases. From 2022 to 2023, the number of human cases doubled and animal cases quadrupled, with cases reported across all areas of Manaus. The expansion of sporotrichosis was observed over a two-year period for nearly the entire area of Manaus, with a significant increase in cases and an association between animal and human cases.

1 January 2025 in Revista do Instituto de Medicina Tropical de São Paulo
Verified
Journal Article
Open access
KAKessia Caroline Souza Alves
Kessia Caroline Souza Alves
EMEmmily Mourao
Emmily Mourao
JMJoyce Marinho Melo
Joyce Marinho Melo
MAMaria Edilene Martins Almeida
Maria Edilene Martins Almeida
JOJuliana Gomes de Souza Oliveira
Juliana Gomes de Souza Oliveira
LMLuis André Mariuba
Luis André Mariuba
For decades, research and development toward malaria vaccine has prioritized infections caused by Plasmodium falciparum, since it is the species responsible for the most severe cases of malaria, which results in a comparatively smaller number of studies devoted to Plasmodium vivax. This disparity is due to complexities inherent in the biology of P. vivax, including the formation of hypnozoites in the pre-erythrocytic phase, difficulties in establishing robust in vitro culture systems, and the absence of fully representative experimental models. Among the antigens investigated for vaccine formulations, the Plasmodium vivax circumsporozoite surface protein (PvCSP) stands out for its immunogenic potential and the partial protection observed in preclinical studies. However, clinical trials with PvCSP-based vaccines have not yet demonstrated a consistent protective response. This review aims to show a historical overview of the studies that have evaluated the potential of vaccines based on the PvCSP protein, as well as to explore the innovative approaches that have been investigated in the last decade to overcome the challenges and advance the development of an effective vaccine against malaria caused by P. vivax.

1 January 2024 in Anais da Academia Brasileira de Ciências
Verified
Journal Article
Open access
PDF file
HAHelber A. Astolpho
Helber A. Astolpho
LMLuis André Mariuba
Luis André Mariuba
YCYury Oliveira Chaves
Yury Oliveira Chaves
JGJuliane Glória
Juliane Glória
MAMaria Edilene M. DE Almeida
Maria Edilene M. DE Almeida
POPatrícia P. Orlandi
Patrícia P. Orlandi
The enterotoxigenic Escherichia coli (ETEC) strain is one of the most frequent causative agents of childhood diarrhea and travelers’ diarrhea in low-and middle-income countries. Among the virulence factors secreted by ETEC, the exoprotein EtpA has been described as an important. In the present study, a new detection tool for enterotoxigenic E. coli bacteria using the EtpA protein was developed. Initially, antigenic sequences of the EtpA protein were selected via in silico prediction. A chimeric recombinant protein, corresponding to the selected regions, was expressed in an E. coli host, purified and used for the immunization of mice. The specific recognition of anti-EtpA IgG antibodies generated was evaluated using flow cytometry. The tests demonstrated that the antibodiesdeveloped were able to recognize the native EtpA protein. By coupling these antibodies to magnetic beads for the capture and detection of ETEC isolates, cytometric analyses showed an increase in sensitivity, specificity and the effectiveness of the method of separation and detection of these pathogens. This is the first report of the use of this methodology for ETEC separation. Future trials may indicate their potential use for isolating these and other pathogens in clinical samples, thus accelerating the diagnosis and treatment of diseases.

1 January 2026 in Revista do Instituto de Medicina Tropical de São Paulo
Verified
Journal Article
Open access
MJMichele Silva de Jesus
Michele Silva de Jesus
MAMaria Edilene Martins de Almeida
Maria Edilene Martins de Almeida
LMLuis André Mariuba
Luis André Mariuba
Leptospirosis is a zoonosis with global distribution caused by spirochetes of the genus Leptospira. In regions with poor sanitation, leptospirosis is considered a neglected disease, resulting in approximately one million cases and thousands of deaths annually. Transmission occurs mainly through contact with the urine of infected rodents, and clinical manifestations range from mild symptoms to the severe form known as Weil’s disease. Although licensed vaccines are available, they are targeted at specific risk groups. Bacterins are composed of specific serovars, induce a short-term immune response, and may cause adverse reactions. Advances in molecular biology-including sequencing of the Leptospira genome-have spurred the development of new vaccination strategies, particularly protein subunit vaccines. These vaccines are based on proteins located in the outer membrane of pathogenic Leptospira species. These antigens are expressed in prokaryotic hosts, exhibit high immunogenicity, and, because they are directly exposed to the host’s immune system, are considered promising targets for the development of safer and more effective vaccines. Among the main antigens studied, the most notable are LipL32, LipL41, OmpL1, OmpL37, Loa22, LigA, and LigB. However, the identification of antigens capable of inducing an effective immune response while containing conserved regions across different serovars remains a major challenge in developing a universal vaccine against leptospirosis. This review presents the principal outer membrane proteins of pathogenic Leptospira that are considered promising candidates for new vaccine formulations, as well as their role in inducing the immune response in the human host.